WallStSmart

Alcon AG (ALC)vsAzenta Inc (AZTA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 1648% more annual revenue ($10.40B vs $595.03M). ALC leads profitability with a 9.4% profit margin vs -10.1%. AZTA appears more attractively valued with a PEG of 0.53. AZTA earns a higher WallStSmart Score of 57/100 (C).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 7.3Quality: 7.3
Piotroski: 4/9

AZTA

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 2.5Value: 8.0Quality: 8.5
Piotroski: 5/9Altman Z: 4.65
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-489.8%)

Margin of Safety

-489.8%

Fair Value

$13.46

Current Price

$75.26

$61.80 premium

UndervaluedFair: $13.46Overvalued
AZTAOvervalued (-12.2%)

Margin of Safety

-12.2%

Fair Value

$27.14

Current Price

$21.86

$5.28 premium

UndervaluedFair: $27.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

AZTA6 strengths · Avg: 9.7/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
80.0%10/10

Revenue surging 80.0% year-over-year

EPS GrowthGrowth
8778.0%10/10

Earnings expanding 8778.0% YoY

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.6510/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.538/10

Growing faster than its price suggests

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

EPS GrowthGrowth
-22.2%2/10

Earnings declined 22.2%

AZTA4 concerns · Avg: 2.8/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Market CapQuality
$1.01B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
1.5%3/10

ROE of 1.5% — below average capital efficiency

Profit MarginProfitability
-10.1%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Debt/Equity, Price/Book.

Bull Case : AZTA

The strongest argument for AZTA centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 80.0% demonstrates continued momentum. PEG of 0.53 suggests the stock is reasonably priced for its growth.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, P/E Ratio, Return on Equity.

Bear Case : AZTA

The primary concerns for AZTA are P/E Ratio, Market Cap, Return on Equity.

Key Dynamics to Monitor

ALC profiles as a value stock while AZTA is a hypergrowth play — different risk/reward profiles.

AZTA carries more volatility with a beta of 1.40 — expect wider price swings.

AZTA is growing revenue faster at 80.0% — sustainability is the question.

ALC generates stronger free cash flow (489M), providing more financial flexibility.

Bottom Line

AZTA scores higher overall (57/100 vs 49/100) and 80.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Azenta Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Azenta Inc. is a leading provider of sample management solutions and life science tools, specializing in enhancing laboratory efficiencies for the biotechnology and pharmaceutical sectors. Leveraging innovative automated solutions, biorepository services, and advanced storage technologies, the company empowers clients to accelerate drug discovery while maintaining strict regulatory compliance. With a strong focus on cutting-edge technology and collaborative partnerships, Azenta is strategically positioned to capitalize on growth opportunities within the expanding global life sciences market. Its unwavering commitment to advancing scientific research through sophisticated products further reinforces its competitive edge in biobanking and sample management.

Visit Website →

Want to dig deeper into these stocks?